Drug treatments for obesity/Bibliography: Difference between revisions
imported>Rachael Kirkbride No edit summary |
imported>Rachael Kirkbride |
||
| Line 9: | Line 9: | ||
==Primary Research Papers== | ==Primary Research Papers== | ||
1. Rossner S, Sjostrom L, Noack R, Meinders A, Noseda G.(2000). Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. ''Obesity Research''.8:41-61 ''"Orlistat administered for 2 years promotes weight loss and minimizes weight regain. Additionally, orlistat therapy improves lipid profile, blood pressure, and quality of life."'' | |||
Revision as of 10:29, 6 October 2009
- Please sort and annotate in a user-friendly manner. For formatting, consider using automated reference wikification.
Review Articles
1. Magni P. et al. (2009) Feeding behavior in mammals including humans. Ann.N.Y.Acad.Sci. 1163:221-232. PMID 19456343
2. Coutinho W. (2009)The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. Arquivos Brasileiros De Endocrinologia E Metabologia. 53:262-270 "The most widely used anti-obesity agents are sibutramine and orlistat, both available in clinical practice for about a decade."
Primary Research Papers
1. Rossner S, Sjostrom L, Noack R, Meinders A, Noseda G.(2000). Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obesity Research.8:41-61 "Orlistat administered for 2 years promotes weight loss and minimizes weight regain. Additionally, orlistat therapy improves lipid profile, blood pressure, and quality of life."